Tien-Li Lee

CIK: 0001940120

Transaction Breakdown

Open Market Buys (P)7 (58.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (16.7%)

Derivative conversions

Awards (A)2 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)1 (8.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AARD

Aardvark Therapeutics, Inc.

DirectorOfficer10% Owner

Discretionary Trading P&L

Holdings

Transaction History (12 total)

AARD
Aardvark Therapeutics, Inc.
Feb 9, 2026
Award(A)
Stock option (right to buy)
Direct
203.9K shares-
AARD
Aardvark Therapeutics, Inc.
Dec 11, 2025
Purchase(P)
Direct
7K shares at avg. $14.48$101K
AARD
Aardvark Therapeutics, Inc.
Oct 15, 2025
Exercise(M)
Direct
1.2K shares at avg. $4.24$5K
AARD
Aardvark Therapeutics, Inc.
Sep 15, 2025
Purchase(P)
Direct
3.5K shares at avg. $9.94$35K
AARD
Aardvark Therapeutics, Inc.
Sep 15, 2025
Purchase(P)
Direct
6.5K shares at avg. $9.51$62K
AARD
Aardvark Therapeutics, Inc.
Sep 12, 2025
Purchase(P)
Direct
5K shares at avg. $8.50$43K
AARD
Aardvark Therapeutics, Inc.
Sep 11, 2025
Purchase(P)
Direct
6K shares at avg. $7.82$47K
AARD
Aardvark Therapeutics, Inc.
Sep 10, 2025
Purchase(P)
Direct
9K shares at avg. $7.91$71K
AARD
Aardvark Therapeutics, Inc.
Aug 28, 2025
Exercise(M)
Direct
17.2K shares at avg. $4.24$73K
AARD
Aardvark Therapeutics, Inc.
Jun 11, 2025
Award(A)
Stock option (right to buy)
Direct
549.5K shares-
AARD
Aardvark Therapeutics, Inc.
Feb 14, 2025
Purchase(P)
Direct
16.5K shares at avg. $16.00$265K
AARD
Aardvark Therapeutics, Inc.
Feb 14, 2025
Conversion(C)
Direct
41.3K shares-

		Type	Shares	Price		Ownership
Feb 9, 2026	AARD Aardvark Therapeutics, Inc.	Award(A) Stock option (right to buy)	203,851	-	-	Direct
Dec 11, 2025	AARD Aardvark Therapeutics, Inc.	Purchase(P)	7,000	$14.48	$101,395	Direct
Oct 15, 2025	AARD Aardvark Therapeutics, Inc.	Exercise(M)	1,229	$4.24	$5,211	Direct
Sep 15, 2025	AARD Aardvark Therapeutics, Inc.	Purchase(P)	3,500	$9.94	$34,805	Direct
Sep 15, 2025	AARD Aardvark Therapeutics, Inc.	Purchase(P)	6,500	$9.51	$61,819	Direct
Sep 12, 2025	AARD Aardvark Therapeutics, Inc.	Purchase(P)	5,000	$8.50	$42,516	Direct
Sep 11, 2025	AARD Aardvark Therapeutics, Inc.	Purchase(P)	6,000	$7.82	$46,926	Direct
Sep 10, 2025	AARD Aardvark Therapeutics, Inc.	Purchase(P)	9,000	$7.91	$71,213	Direct
Aug 28, 2025	AARD Aardvark Therapeutics, Inc.	Exercise(M)	17,209	$4.24	$72,966	Direct
Jun 11, 2025	AARD Aardvark Therapeutics, Inc.	Award(A) Stock option (right to buy)	549,534	-	-	Direct
Feb 14, 2025	AARD Aardvark Therapeutics, Inc.	Purchase(P)	16,542	$16.00	$264,672	Direct
Feb 14, 2025	AARD Aardvark Therapeutics, Inc.	Conversion(C)	41,303	-	-	Direct

1-12 of 12 transactions

About Lee Tien-Li

Lee Tien-Li (SEC CIK 0001940120) files insider reports with the SEC as Chief Executive Officer of Aardvark Therapeutics, Inc. (AARD).

Signal8 holds 9 ownership filings by Lee Tien-Li (1 Form 3, 8 Form 4), filed between Feb 12, 2025 and Feb 11, 2026. Those filings report 12 transactions, from Feb 14, 2025 to Feb 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lee Tien-Li's filings is in SAN DIEGO, CA.

Recent filings by Lee Tien-Li

Feb 9, 2026: Grant or award of AARD derivative securities (Form 4, code A).
Dec 11, 2025: Open-market purchase of AARD shares (Form 4, code P).
Oct 15, 2025: Option exercise of AARD shares (Form 4, code M).
Sep 15, 2025: Open-market purchases of AARD shares (2 lines, Form 4, code P).
Sep 12, 2025: Open-market purchase of AARD shares (Form 4, code P).

Other insiders filing for Aardvark Therapeutics, Inc. (AARD)

Zhang Zhongwei, Director
Sun Nelson
Chi Jeffrey, Director
Graf Susan E, Director
Baynes Roy D., Director
Tong Victor Edward Jr, Director

How to read Form 4 transaction codes